Gilead and Merck’s latest trial success and flop - Scorecard - MDSpire

Gilead and Merck’s latest trial success and flop

  • By

  • Elaine Chen

  • June 9, 2026

  • 0 min

Share

Clinical Scorecard: Gilead and Merck's Recent Clinical Trial Outcomes: Successes and Challenges

At a Glance

CategoryDetail
Condition
Key MechanismsCombination of antivirals islatravir and lenacapavir for HIV; Trodelvy targets TROP-2 in lung cancer.
Target Population
Care Setting

Key Highlights

  • Gilead and Merck's HIV treatment shows promise with once-weekly dosing.
  • Trodelvy plus Keytruda failed to improve progression-free survival in lung cancer.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Clinical Best Practices

            Related Resources & Content

              Original Source(s)

              Gilead and Merck’s latest trial success and flop

              • by Elaine Chen

              • June 9, 2026

              Related Content

              This Week’s Biopharma News: Big Moves in Bispecifics

              Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

              • June 9, 2026

              • 5 min
              Rearming mesenchymal stem cells with engineering strategies to combat cancer

              A multi-task deep learning framework for simultaneous prediction of microsatellite instability and tumor mutational burden in gastric cancer from histopathological images